Ling Ma, MD
Hematology & Oncology · Lakewood, CONPI 1063617454
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), consulting fees and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by AstraZeneca at 32.5% of the total.
Across 122 payments — averaging $55.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novartis$1K
- Medtronic$418
- Immunogen, Inc.$278
- Pharmacyclics LLC, An Abbvie Company$273
- AbbVie$201
- plus $2K from 32 others
Across 158 payments — averaging $11,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- Genentech, Inc.$197K
- Clovis Oncology, Inc.$183K
- Gilead$128K
- Astrazeneca UK Limited$35K
- AstraZeneca$31K
- plus $25K from 4 others
What the payments were for
- Consulting fees$3,02545%
- Food & beverage$3,66454%
- Education$1072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $2,210 |
| Novartis | 7 | $1,488 |
| Medtronic | 8 | $418 |
| Immunogen, Inc. | 3 | $278 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $273 |
| AbbVie | 8 | $201 |
| Genentech USA, Inc. | 7 | $168 |
| Gilead(2 entities) | 5 | $143 |
| GSK | 5 | $134 |
| Pfizer | 6 | $122 |
| Astellas Pharma US Inc | 5 | $122 |
| Tempus AI, Inc | 1 | $117 |
| Iovance Biotherapeutics, Inc. | 5 | $104 |
| Tersera Therapeutics LLC | 3 | $98 |
| Ipsen Biopharmaceuticals, Inc | 1 | $83 |
| Bristol Myers Squibb | 5 | $81 |
| Eisai Inc. | 3 | $78 |
| Johnson & Johnson(2 entities) | 3 | $72 |
| Exelixis Inc. | 2 | $64 |
| Sanofi | 1 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Blueprint Medicines Corporation | 1 | $46 |
| Bayer | 2 | $45 |
| Stemline Therapeutics Inc. | 2 | $44 |
| Merck | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Novocure Inc. | 1 | $29 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Amgen | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$1,665
- PIQRAY$1,360
- OSTEOCOOL RF ABLATION SYSTEM$282
- Elahere$261
- IMBRUVICA$125
How this compares
$6,796 in reported general payments places this provider in the 65th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 42 | $1,030,038 |
| RevlimidLenalidomide | 45 | $766,511 |
| Lenalidomide | 51 | $708,300 |
| VerzenioAbemaciclib | 24 | $360,992 |
| BrukinsaZanubrutinib | 15 | $227,131 |
| ZejulaNiraparib Tosylate | 12 | $208,191 |
| JakafiRuxolitinib Phosphate | 17 | $180,201 |
| CalquenceAcalabrutinib Maleate | 13 | $150,610 |
| EliquisApixaban | 95 | $86,654 |
| XareltoRivaroxaban | 54 | $59,415 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $48,519 |
| Everolimus | 17 | $27,831 |
| Enoxaparin Sodium | 59 | $11,702 |
| Anastrozole | 818 | $9,875 |
| Exemestane | 50 | $5,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $81 | $766,51145 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $23 | $361,38177 claims |
| GSKZejula | $134 | $208,19112 claims |
| AstraZenecaCalquence | $2,210 | $150,61013 claims |
| PfizerEliquis | $122 | $86,65495 claims |
| Johnson & JohnsonXarelto | $72 | $59,41554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Lakewood
- Nauman MoazzamLakewood$80K
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.